CureVac (1CVAC) Stock Overview
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
1CVAC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
CureVac N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.48 |
| 52 Week High | US$4.94 |
| 52 Week Low | US$2.15 |
| Beta | 1.77 |
| 1 Month Change | -23.70% |
| 3 Month Change | -23.43% |
| 1 Year Change | 25.32% |
| 3 Year Change | -45.19% |
| 5 Year Change | n/a |
| Change since IPO | -91.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1CVAC | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -19.9% | 1.4% | 1.8% |
| 1Y | 25.3% | 20.8% | 30.6% |
Return vs Industry: 1CVAC exceeded the Italian Biotechs industry which returned 17.6% over the past year.
Return vs Market: 1CVAC matched the Italian Market which returned 25.7% over the past year.
Price Volatility
| 1CVAC volatility | |
|---|---|
| 1CVAC Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 7.1% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: 1CVAC has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1CVAC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 904 | Alexander Zehnder | www.curevac.com |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane.
CureVac N.V. Fundamentals Summary
| 1CVAC fundamental statistics | |
|---|---|
| Market cap | €923.98m |
| Earnings (TTM) | €128.82m |
| Revenue (TTM) | €70.74m |
Is 1CVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1CVAC income statement (TTM) | |
|---|---|
| Revenue | €70.74m |
| Cost of Revenue | €4.75m |
| Gross Profit | €65.99m |
| Other Expenses | -€62.83m |
| Earnings | €128.82m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 93.29% |
| Net Profit Margin | 182.11% |
| Debt/Equity Ratio | 0% |
How did 1CVAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/17 20:16 |
| End of Day Share Price | 2025/12/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CureVac N.V. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Emmanuel Papadakis | Deutsche Bank |